-
1.发明授权公开(公告)号：US09353186B2
公开(公告)日：2016-05-31
申请号：US14123517
申请日：2012-05-31
Applicant: Christoph Freiberg , Christiane Otto , Lars Linden , Axel Harrenga , Mark Trautwein , Simone Greven , Andreas Wilmen
Inventor： Christoph Freiberg , Christiane Otto , Lars Linden , Axel Harrenga , Mark Trautwein , Simone Greven , Andreas Wilmen
IPC: C07K16/28 , A61K39/395 , A61K45/06 , A61K39/00
CPC classification number: C07K16/2869 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K16/3015 , C07K2317/21 , C07K2317/33 , C07K2317/34 , C07K2317/565 , C07K2317/73 , C07K2317/76 , C07K2317/92
Abstract: The neutralizing prolactin receptor antibody Mat3, and antigen binding fragments, pharmaceutical compositions containing them and their use in the treatment or prevention of benign disorders and indications mediated by the prolactin receptor such as endometriosis, adenomyosis, non-hormonal female contraception, benign breast disease and mastalgia, lactation inhibition, benign prostate hyperplasia, fibroids, hyper- and normoprolactinemic hair loss, and cotreatment in combined hormone therapy to inhibit mammary epithelial cell proliferation and for the treatment and prevention of antiestrogen-resistant breast cancer. The antibody blocks prolactin receptor-mediated signalling.
Abstract translation: 中和催乳素受体抗体Mat3和抗原结合片段，含有它们的药物组合物及其用于治疗或预防由催乳素受体介导的良性疾病和适应症的用途，例如子宫内膜异位症，子宫腺肌症，非激素雌性避孕，良性乳腺疾病和 乳腺，泌乳抑制，良性前列腺增生，肌瘤，高血压和正常泌乳素脱发，以及联合激素治疗中的联合抑制乳腺上皮细胞增殖和治疗和预防抗雌激素抵抗性乳腺癌。 该抗体阻断催乳素受体介导的信号传导。
-
公开(公告)号：US20140050743A1
公开(公告)日：2014-02-20
申请号：US13980431
申请日：2012-01-17
Applicant: Frank Dittmer , Anja Buchmüller , Christoph Gerdes , Adrian Tersteegen , Mark Jean Gnoth , Lars Linden , Axel Harrenga , Joanna Grudzinska-Goebel , Mario Jeske , Martina Schäfer , Jörg Birkenfeld , Holger Paulsen , Ricarda Finnern , Anke Mayer-Bartschmid , Andrea Eicker , Simone Greven , Susanne Steinig
Inventor： Frank Dittmer , Anja Buchmüller , Christoph Gerdes , Adrian Tersteegen , Mark Jean Gnoth , Lars Linden , Axel Harrenga , Joanna Grudzinska-Goebel , Mario Jeske , Martina Schäfer , Jörg Birkenfeld , Holger Paulsen , Ricarda Finnern , Anke Mayer-Bartschmid , Andrea Eicker , Simone Greven , Susanne Steinig
IPC: C07K16/44
CPC classification number: C07K16/44 , A61K2039/505 , A61K2300/00 , C07K2317/55 , C07K2317/76
Abstract: The present invention relates to the identification and use of antigen-binding regions, antibodies, antigen-binding antibody fragments and antibody mimetics, neutralizing the anti-coagulant effect of an anticoagulant in vitro and/or in vivo. Antibodies and functional fragments of the invention and antibody mimetics can be used to specifically reverse the pharmacological effect of an anticoagulant e.g. a FXa inhibitor for therapeutic (antidote) and/or diagnostic purposes. The invention also provides nucleic acid sequences encoding foregoing molecules, vectors containing the same, pharmaceutical compositions and kits with instructions for use.
Abstract translation: 本发明涉及抗原结合区，抗体，抗原结合抗体片段和抗体模拟物的鉴定和用途，其中和抗凝血剂在体外和/或体内的抗凝血作用。 本发明的抗体和功能片段和抗体模拟物可用于特异性地逆转抗凝血剂的药理学作用。 用于治疗（解毒剂）和/或诊断目的的FXa抑制剂。 本发明还提供了编码前述分子的核酸序列，含有该分子的载体，药物组合物和具有使用说明书的试剂盒。
-
公开(公告)号：US20130022606A1
公开(公告)日：2013-01-24
申请号：US13514995
申请日：2010-11-18
Applicant: Christiane Otto , Siegmund Wolf , Christoph Freiberg , Axel Harrenga , Simone Greven , Mark Trautwein , Sandra Bruder
Inventor： Christiane Otto , Siegmund Wolf , Christoph Freiberg , Axel Harrenga , Simone Greven , Mark Trautwein , Sandra Bruder
IPC: A61K39/395 , C07H21/00 , A61P15/00 , A61P13/08 , A61P17/14 , C12P21/02 , A61P15/14 , C12N15/63 , C12N5/10 , C12N1/19 , C12N1/21 , C07K16/28 , A61P15/18
CPC classification number: A61K39/3955 , A61K45/06 , A61K2039/505 , C07K16/28 , C07K16/2866 , C07K16/2869 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/76
Abstract: The present invention is directed to the neutralizing prolactin receptor antibody 006-H07, and antigen binding fragments, pharmaceutical compositions containing them and their use in the treatment or prevention of benign disorders and indications mediated by the prolactin receptor such as endometriosis, adenomyosis, non-hormonal female contraception, benign breast disease and mastalgia, lactation inhibition, benign prostate hyperplasia, fibroids, hyper- and normoprolactinemic hair loss, and cotreatment in combined hormone therapy to inhibit mammary epithelial cell proliferation. The antibodies of the invention block prolactin receptor-mediated signaling.
Abstract translation: 本发明涉及中和催乳素受体抗体006-H07和抗原结合片段，含有它们的药物组合物及其用于治疗或预防由催乳素受体介导的良性病症和适应症的用途，例如子宫内膜异位症，子宫腺肌症， 激素女性避孕，良性乳腺疾病和乳腺疾病，哺乳期抑制，良性前列腺增生，纤维瘤，高血压和正常泌乳素脱发，联合激素治疗联合抑制乳腺上皮细胞增殖。 本发明的抗体阻断催乳素受体介导的信号传导。
-
公开(公告)号：US20090170766A1
公开(公告)日：2009-07-02
申请号：US12224759
申请日：2007-03-01
Applicant: Felix Oehme , Heiner Apeler , Frank Dittmer , Jürgen Franz , Axel Harrenga , Michael Sperzel , Simone Greven , Jürgen Lenz
Inventor： Felix Oehme , Heiner Apeler , Frank Dittmer , Jürgen Franz , Axel Harrenga , Michael Sperzel , Simone Greven , Jürgen Lenz
CPC classification number: C07K14/8114
Abstract: The present invention relates to chimeras of human tissue factor inhibitor domain 1 with natural and non-natural Kunitz domains, and their preparation and use.
Abstract translation: 本发明涉及具有天然和非天然Kunitz结构域的人组织因子抑制剂结构域1的嵌合体及其制备和用途。
-
公开(公告)号：US20130272968A1
公开(公告)日：2013-10-17
申请号：US13514992
申请日：2010-11-18
Applicant: Christiane Otto , Siegmund Wolf , Christoph Freiberg , Axel Harrenga , Simone Greven , Mark Trautwein , Sandra Bruder , Andrea Eicker , Andreas Wilmen
Inventor： Christiane Otto , Siegmund Wolf , Christoph Freiberg , Axel Harrenga , Simone Greven , Mark Trautwein , Sandra Bruder , Andrea Eicker , Andreas Wilmen
IPC: A61K39/395 , A61K45/06
CPC classification number: A61K39/3955 , A61K45/06 , A61K2039/505 , C07K16/28 , C07K16/2866 , C07K16/2869 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/76
Abstract: The present invention is directed to the neutralizing prolactin receptor antibody 006-H08, as well as maturated forms thereof, and antigen-binding fragments, pharmaceutical compositions containing them and their use in the treatment or prevention of benign disorders and indications mediated by the prolactin receptor such as endometriosis, adenomyosis, non-hormonal female contraception, benign breast disease and mastalgia, lactation inhibition, benign prostate hyperplasia, fibroids, hyper- and normoprolactinemic hair loss, and cotreatment in combined hormone therapy to inhibit mammary epithelial cell proliferation. The antibodies of the invention block prolactin receptor-mediated signaling.
Abstract translation: 本发明涉及中和催乳素受体抗体006-H08以及其成熟形式，以及抗原结合片段，含有它们的药物组合物及其在治疗或预防良性病症和由催乳素受体介导的适应症中的用途 子宫内膜异位症，子宫腺肌症，非激素女性避孕，良性乳腺疾病和乳腺疾病，哺乳期抑制，良性前列腺增生，纤维瘤，高血压和正常泌乳素脱发，联合激素治疗联合抑制乳腺上皮细胞增殖。 本发明的抗体阻断催乳素受体介导的信号传导。
-
Patent Agency Ranking
公开(公告)号：US20130122024A1
公开(公告)日：2013-05-16
申请号：US13451916
申请日：2012-04-20
Applicant: Hans-Georg LERCHEN , Beatrix STELTE-LUDWIG , Sven GOLFIER , Charlotte Christine KOPITZ , Rudolf BEIER , Sherif EL SHEIKH , Iring HEISLER , Axel HARRENGA , Karl-Heinz THIERAUCH , Joachim SCHUHMACHER , Sandra BRUDER , Simone GREVEN , Lars LINDEN , Jörg WILLUDA , Christoph MAHLERT , Heike PETRUL , Hannah JÖRIßEN , Sandra Borkowski
Inventor： Hans-Georg LERCHEN , Beatrix STELTE-LUDWIG , Sven GOLFIER , Charlotte Christine KOPITZ , Rudolf BEIER , Sherif EL SHEIKH , Iring HEISLER , Axel HARRENGA , Karl-Heinz THIERAUCH , Joachim SCHUHMACHER , Sandra BRUDER , Simone GREVEN , Lars LINDEN , Jörg WILLUDA , Christoph MAHLERT , Heike PETRUL , Hannah JÖRIßEN , Sandra Borkowski
IPC: C07K16/18 , A61K39/395 , A61K45/06 , C07K7/06
CPC classification number: A61K31/40 , A61K31/4025 , A61K31/404 , A61K31/422 , A61K31/4245 , A61K31/5355 , A61K31/536 , A61K31/537 , A61K31/5377 , A61K39/3955 , A61K45/06 , A61K47/542 , A61K47/6803 , A61K47/6851 , A61K47/6859 , A61K47/6869 , A61K47/6889 , C07K5/0205 , C07K5/0207 , C07K5/06 , C07K5/06034 , C07K5/06052 , C07K5/0606 , C07K7/02 , C07K7/06 , C07K16/18 , C07K16/28 , C07K16/2812 , C07K16/2863 , C07K16/30 , C07K2317/21 , C07K2317/24 , C07K2317/565 , C07K2317/76
Abstract: The present application relates to new binder-drug conjugates (ADCs) of N,N-dialkylauristatins that are directed against the target mesothelin, to active metabolites of these ADCs, to processes for preparing these ADCs, to the use of these ADCs for treating and/or preventing illnesses, and also to the use of these ADCs for producing medicaments for treating and/or preventing illnesses, more particularly hyperproliferative and/or angiogenic diseases such as, for example, cancer diseases. Such treatments may be practised as a monotherapy or else in combination with other medicaments or further therapeutic measures.
Abstract translation: 本申请涉及针对靶间皮素的N，N-二烷基海马素的新粘合剂 - 药物偶联物（ADC），这些ADC的活性代谢物，制备这些ADC的方法，以及使用这些ADC用于治疗和 /或预防疾病，以及使用这些ADC用于制备用于治疗和/或预防疾病的药物，更特别是过度增殖和/或血管生成疾病，例如癌症疾病。 这样的治疗可以作为单一疗法来实施，或者与其它药物组合或进一步的治疗措施。
-
公开(公告)号：US20120321632A1
公开(公告)日：2012-12-20
申请号：US13514991
申请日：2010-11-18
Applicant: Christiane Otto , Siegmund Wolf , Christoph Freiberg , Axel Harrenga , Simone Greven , Mark Trautwein , Sandra Bruder , Andrea Eicker , Andreas Wilmen
Inventor： Christiane Otto , Siegmund Wolf , Christoph Freiberg , Axel Harrenga , Simone Greven , Mark Trautwein , Sandra Bruder , Andrea Eicker , Andreas Wilmen
CPC classification number: A61K39/3955 , A61K45/06 , A61K2039/505 , C07K16/28 , C07K16/2866 , C07K16/2869 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/76
Abstract: The present invention is directed to pharmaceutical compositions containing one or more neutralizing prolactin receptor antibodies and antigen binding fragments, and their use in the treatment or prevention of benign disorders and indications mediated by the prolactin receptor such as endometriosis, adenomyosis, non-hormonal female contraception, benign breast disease and mastalgia, lactation inhibition, benign prostate hyperplasia, fibroids, hyper- and normoprolactinemic hair loss, and cotreatment in combined hormone therapy to inhibit mammary epithelial cell proliferation. The composition of the invention blocks prolactin receptor-mediated signaling.
Abstract translation: 本发明涉及含有一种或多种中和催乳素受体抗体和抗原结合片段的药物组合物，以及它们在治疗或预防由催乳素受体介导的良性疾病和适应症的用途，例如子宫内膜异位，子宫腺肌症，非激素雌性避孕 ，良性乳腺疾病和乳腺疾病，哺乳期抑制，良性前列腺增生，肌瘤，高血压和正常泌乳素脱发，以及联合激素治疗中的抑制乳腺上皮细胞增殖的联合治疗。 本发明的组合物阻断催乳素受体介导的信号传导。
-
公开(公告)号：US09241989B2
公开(公告)日：2016-01-26
申请号：US13514996
申请日：2010-11-18
Applicant: Christiane Otto , Siegmund Wolf , Christoph Freiberg , Axel Harrenga , Simone Greven , Mark Trautwein , Sandra Bruder , Andrea Eicker , Andreas Wilmen
Inventor： Christiane Otto , Siegmund Wolf , Christoph Freiberg , Axel Harrenga , Simone Greven , Mark Trautwein , Sandra Bruder , Andrea Eicker , Andreas Wilmen
IPC: A61K39/395 , C07K16/28 , A61K45/06 , A61K39/00
CPC classification number: A61K39/3955 , A61K45/06 , A61K2039/505 , C07K16/28 , C07K16/2866 , C07K16/2869 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/76
Abstract: The present invention is directed to the neutralizing prolactin receptor antibody 005-C04, as well as maturated forms thereof, and antigen binding fragments, pharmaceutical compositions containing them and their use in the treatment or prevention of benign disorders and indications mediated by the prolactin receptor such as endometriosis, adenomyosis, non-hormonal female contraception, benign breast disease and mastalgia, lactation inhibition, benign prostate hyperplasia, fibroids, hyper- and normoprolactinemic hair loss, and cotreatment in combined hormone therapy to inhibit mammary epithelial cell proliferation. The antibodies of the invention block prolactin receptor-mediated signaling.
Abstract translation: 本发明涉及中和催乳素受体抗体005-C04及其成熟形式，以及抗原结合片段，含有它们的药物组合物及其用于治疗或预防由催乳素受体介导的良性疾病和适应症的用途，例如 作为子宫内膜异位症，子宫腺肌症，非荷尔蒙女性避孕，良性乳腺疾病和乳腺疾病，哺乳期抑制，良性前列腺增生，肌瘤，高血压和正常泌乳素脱发，联合激素治疗联合抑制乳腺上皮细胞增殖。 本发明的抗体阻断催乳素受体介导的信号传导。
-
公开(公告)号：US20140127240A1
公开(公告)日：2014-05-08
申请号：US14113070
申请日：2012-04-20
Applicant: Hans-Georg Lerchen , Lars Linden , Sherif El Sheikh , Jörg Willuda , Charlotte C. Kopitz , Joachim Schuhmacher , Simone Greven , Christoph Mahlert , Beatrix Stelte-Ludwig , Sven Golfier , Rudolf Beier , Iring Heisler , Axel Harrenga , Karl-Heinz Thierauch , Sandra Bruder , Heike Petrul , Hannah Jörißen , Sandra Brokowski
Inventor： Hans-Georg Lerchen , Lars Linden , Sherif El Sheikh , Jörg Willuda , Charlotte C. Kopitz , Joachim Schuhmacher , Simone Greven , Christoph Mahlert , Beatrix Stelte-Ludwig , Sven Golfier , Rudolf Beier , Iring Heisler , Axel Harrenga , Karl-Heinz Thierauch , Sandra Bruder , Heike Petrul , Hannah Jörißen , Sandra Brokowski
CPC classification number: A61K31/40 , A61K31/4025 , A61K31/404 , A61K31/422 , A61K31/4245 , A61K31/5355 , A61K31/536 , A61K31/537 , A61K31/5377 , A61K39/3955 , A61K45/06 , A61K47/542 , A61K47/6803 , A61K47/6851 , A61K47/6859 , A61K47/6869 , A61K47/6889 , C07K5/0205 , C07K5/0207 , C07K5/06 , C07K5/06034 , C07K5/06052 , C07K5/0606 , C07K7/02 , C07K7/06 , C07K16/18 , C07K16/28 , C07K16/2812 , C07K16/2863 , C07K16/30 , C07K2317/21 , C07K2317/24 , C07K2317/565 , C07K2317/76
Abstract: The present patent application relates to novel binder-drug conjugates (ADCs) of N,N-dialkylauristatins directed against the target epidermal growth factor receptor (EGFR, gene ID 1956), effective metabolites of these ADCs, methods for producing these ADCs, use of these ADCs for treatment and or prevention of diseases as well as the use of these ADCs to produce pharmaceutical drugs for treatment and/or prevention of diseases, in particular hyperproliferative and/or angiogenic diseases such as cancer, for example. Such treatments may be administered as monotherapy or in combination with other pharmaceutical drugs or other therapeutic measures.
Abstract translation: 本专利申请涉及针对靶表皮生长因子受体（EGFR，基因ID 1956）的N，N-二烷基硫酸锡的新型粘合剂 - 药物共轭物（ADC），这些ADC的有效代谢物，制备这些ADC的方法， 这些ADC用于治疗和/或预防疾病，以及使用这些ADC来制备用于治疗和/或预防疾病，特别是过度增生和/或血管发生疾病例如癌症的药物。 这样的治疗可以作为单一疗法或与其它药物或其他治疗措施组合施用。
-
公开(公告)号：US20130171147A1
公开(公告)日：2013-07-04
申请号：US13514993
申请日：2010-11-18
Applicant: Christiane Otto , Siegmund Wolf , Christoph Freiberg , Axel Harrenga , Simone Greven , Mark Trautwein , Sandra Bruder
Inventor： Christiane Otto , Siegmund Wolf , Christoph Freiberg , Axel Harrenga , Simone Greven , Mark Trautwein , Sandra Bruder
IPC: C07K16/28
CPC classification number: A61K39/3955 , A61K45/06 , A61K2039/505 , C07K16/28 , C07K16/2866 , C07K16/2869 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/76
Abstract: The present invention is directed to the neutralizing prolactin receptor antibody 002-H06, and antigen binding fragments, pharmaceutical compositions containing them and their use in the treatment or prevention of benign disorders and indications mediated by the prolactin receptor such as endometriosis, adenomyosis, non-hormonal female contraception, benign breast disease and mastalgia, lactation inhibition, benign prostate hyperplasia, fibroids, hyper- and normoprolactinemic hair loss, and cotreatment in combined hormone therapy to inhibit mammary epithelial cell proliferation. The antibodies of the invention block prolactin receptor-mediated signaling.
Abstract translation: 本发明涉及中和催乳素受体抗体002-H06和抗原结合片段，含有它们的药物组合物及其用于治疗或预防由催乳素受体介导的良性病症和适应症的用途，例如子宫内膜异位症，子宫腺肌症， 激素女性避孕，良性乳腺疾病和乳腺疾病，哺乳期抑制，良性前列腺增生，纤维瘤，高血压和正常泌乳素脱发，联合激素治疗联合抑制乳腺上皮细胞增殖。 本发明的抗体阻断催乳素受体介导的信号传导。
-
-
-
-
-
-
-
-
-
Search Results
16
records
(took 0.028 seconds)
